ClinicalTrials.gg

Program

dexmethylphenidate

Also written as “Dexmethylphenidate Hydrochloride”, “CTx-1301 - Dexmethylphenidate 37.5mg” and “Dexmethylphenidate”.

Its studies are mostly in Attention Deficit Disorder with Hyperactivity · Fasting · Fatigue, led by 4 companies.

Furthest: phase 4, since Mar 1, 202214 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cingulate Therapeutics60 open or runningphase 3since Mar 1, 2022Sep 19, 2019none ahead
Novartis50 open or runningphase 4since Nov 27, 2007Aug 30, 2005none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Jan 26, 2009Jan 26, 2009none ahead
Bristol-Myers Squibb10 open or runningphase 2since Oct 8, 2002Oct 8, 2002none ahead

Also a collaborator on its studies: rho-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 8, 2002First study: phase 2 study in FatigueNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00047476 · 160 enrolled · United States
  2. Aug 30, 2005Novartis's first studies: 2 phase 3 studies in Attention Deficit Disorder with HyperactivityNew to NovartisNovartis · NCT00141063, NCT00141050
  3. Mar 8, 2006Phase 3 study in Attention Deficit Disorder with HyperactivityNovartis · NCT00301236 · 252 enrolled · United States
  4. Nov 27, 2007Phase 4 study in Attention Deficit Disorder with HyperactivityNovartis · NCT00564954 · 86 enrolled · United States
  5. Oct 16, 2008Phase 4 study in Attention Deficit Disorder with HyperactivityNovartis · NCT00776009 · 165 enrolled · United States
  6. Jan 26, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00829712, NCT00829673
  7. Sep 19, 2019Cingulate Therapeutics's first study: phase 2 study in Attention Deficit Disorder with HyperactivityNew to Cingulate TherapeuticsCingulate Therapeutics · NCT04138498 · 45 enrolled · United States
  8. Jun 24, 2020Phase 1 study in FastingCingulate Therapeutics · NCT04449250 · 27 enrolled · United States
  9. Mar 1, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityCingulate Therapeutics · NCT05286762 · 103 enrolled · United States
  10. Nov 14, 2022Phase 3 study in Attention Deficit Disorder with HyperactivityCingulate Therapeutics · NCT05631626 · 26 enrolled · United States
  11. Jun 21, 2023Phase 3 study in Attention Deficit Disorder with HyperactivityCingulate Therapeutics · NCT05924594 · 45 enrolled · United States
  12. Apr 25, 2025Phase 1 study in FastingCingulate Therapeutics · NCT07119073 · 25 enrolled · United States

TargetBeta

“Dopamine transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
BupropionruleGlaxoSmithKlinephase 429
AmphetamineruleTris Pharmaphase 48

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07119073Fasting · United States1CompletedCingulate TherapeuticsDec 21, 202425
NCT05924594Attention Deficit Disorder with Hyperactivity · United States3SuspendedCingulate TherapeuticsFeb 202745
NCT05631626Attention Deficit Disorder with Hyperactivity · United States3CompletedCingulate TherapeuticsJun 13, 202326
NCT05286762Attention Deficit Disorder with Hyperactivity · United States3CompletedCingulate TherapeuticsFeb 29, 2024103
NCT04449250Fasting · United States1CompletedCingulate TherapeuticsOct 14, 202227
NCT04138498Attention Deficit Disorder with Hyperactivity · United States2CompletedCingulate TherapeuticsMar 6, 202045
NCT00829712Healthy · United States1CompletedTeva Pharmaceutical IndustriesJun 200424
NCT00829673Healthy · United States1CompletedTeva Pharmaceutical IndustriesJun 200424
NCT00776009Attention Deficit Disorder with Hyperactivity · United States4CompletedNovartisDec 2008165
NCT00564954Attention Deficit Disorder with Hyperactivity · United States4CompletedNovartisNov 200786
NCT00301236Attention Deficit Disorder with Hyperactivity · United States3CompletedNovartis252
NCT00141063Attention Deficit Disorder with Hyperactivity · United States3CompletedNovartis90
NCT00141050Attention Deficit Disorder with Hyperactivity · United States3CompletedNovartis90
NCT00047476Fatigue · United States2CompletedBristol-Myers Squibb160

How it is read

Names in the registry

  • “Dexmethylphenidate Hydrochloride”, 4 entries
  • “CTx-1301 - Dexmethylphenidate 37.5mg”, 2 entries
  • “Dexmethylphenidate”, 2 entries
  • “Focalin XR”, 2 entries
  • “CTx-1301 - Dexmethylphenidate 25mg”, 1 entry

Codes read as this program: CTX1301.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.